Common use
Daklinza is a prescription direct-acting antiviral medication containing daclatasvir 60 mg as its active ingredient. It is specifically indicated for the treatment of chronic hepatitis C virus (HCV) infection and represents a major advancement in modern hepatitis C treatment. If you are looking to buy Daklinza online, you are choosing a clinically proven NS5A inhibitor that targets the hepatitis C virus at a critical stage of its replication cycle.

Daclatasvir works by inhibiting the HCV nonstructural protein NS5A, a multifunctional protein essential for viral RNA replication and virion assembly. Research has demonstrated that daclatasvir targets two distinct steps of the viral replication process, enabling a rapid and significant decline in HCV RNA levels in the blood. This dual mechanism of action makes Daklinza one of the most effective direct-acting antiviral agents available for HCV medication regimens.

As a Daklinza generic, this medication is indicated for use in combination with sofosbuvir, with or without ribavirin, for the treatment of patients with chronic hepatitis C genotype 1 or genotype 3 infections. The combination therapy approach has demonstrated high sustained virological response (SVR) rates — effectively meaning a functional cure for many patients with chronic hepatitis C. When you buy daclatasvir as part of a comprehensive antiviral treatment plan, you are taking a significant step toward clearing the virus and protecting your long-term liver health.

Important: Women of childbearing potential should avoid pregnancy during combination treatment with Daklinza, sofosbuvir, and ribavirin, and for 6 months following completion of treatment.

Dosage and direction
The recommended dosage of Daklinza is 60 mg taken orally once daily, with or without food. Consistency in daily dosing is important for maintaining therapeutic drug levels and achieving optimal antiviral efficacy in your hepatitis C treatment.

Recommended treatment regimens and duration for Daklinza by genotype:

Genotype 1:
Without cirrhosis — Daklinza + sofosbuvir for 12 weeks
Compensated (Child-Pugh A) cirrhosis — Daklinza + sofosbuvir for 12 weeks
Decompensated (Child-Pugh B or C) cirrhosis — Daklinza + sofosbuvir + ribavirin for 12 weeks
Post-transplant — Daklinza + sofosbuvir + ribavirin for 12 weeks

Genotype 3:
Without cirrhosis — Daklinza + sofosbuvir for 12 weeks
Compensated (Child-Pugh A) or decompensated (Child-Pugh B or C) cirrhosis — Daklinza + sofosbuvir + ribavirin for 12 weeks
Post-transplant — Daklinza + sofosbuvir + ribavirin for 12 weeks

Dose adjustments may be necessary when Daklinza is co-administered with strong CYP3A inhibitors (reduce to 30 mg once daily) or moderate CYP3A inducers (increase to 90 mg once daily). For specific dosage recommendations for sofosbuvir and ribavirin, refer to their respective prescribing information. Always follow your physician's individualized HCV medication plan for the best outcomes.

Precautions
When using Daklinza for chronic hepatitis C treatment, be aware that concomitant use with other drugs may result in significant drug interactions. Some interactions may lead to loss of therapeutic effect of daclatasvir and possible development of viral resistance, while others may require dosage adjustments or increased monitoring for adverse reactions.

A particularly important safety concern involves the co-administration of amiodarone with sofosbuvir-containing regimens including Daklinza. Postmarketing surveillance has identified cases of symptomatic bradycardia (dangerously slow heart rate) and cases requiring pacemaker intervention. A fatal cardiac arrest has been reported in a patient receiving a sofosbuvir-containing regimen. Bradycardia generally resolved after discontinuation of HCV treatment, though the underlying mechanism remains unknown.

For patients currently taking amiodarone who have no alternative treatment options and will be co-administered Daklinza and sofosbuvir: cardiac monitoring is required for the first 48 hours of co-administration, followed by daily outpatient or self-monitoring of heart rate for at least the first 2 weeks of treatment. Patients should be counseled to recognize symptoms of bradycardia and instructed to seek immediate medical attention if they occur.

Before you buy Daklinza online, discuss all current medications with your healthcare provider to ensure safe use of this direct-acting antiviral.

Contraindications
Daklinza is contraindicated with the following medications due to the risk of significantly reduced daclatasvir levels and loss of antiviral efficacy:

Anticonvulsants — phenytoin, carbamazepine (strong CYP3A inducers)
Antimycobacterial agents — rifampin (a potent CYP3A inducer)
Herbal products — St. John's wort (Hypericum perforatum), which strongly induces CYP3A metabolism

Using Daklinza with any of these contraindicated agents may result in treatment failure and the development of drug-resistant HCV strains. Always inform your physician of all medications and supplements you take before starting hepatitis C treatment with this NS5A inhibitor.

Possible side effect
The most commonly reported side effects during clinical trials of Daklinza in combination with sofosbuvir (with or without ribavirin) and other HCV treatment regimens include: fatigue, headache, nausea, diarrhea, insomnia, decreased appetite, dry skin, pruritus (itching), rash, asthenia (weakness), irritability, myalgia (muscle pain), alopecia (hair loss), influenza-like illness, pyrexia (fever), cough, and dyspnea (shortness of breath).

Laboratory abnormalities observed during treatment may include anemia, neutropenia, thrombocytopenia, and lymphopenia. These are generally manageable and resolve after completion of the treatment course.

If you are taking Daklinza with sofosbuvir and also using a heart rhythm medication called amiodarone, be aware that this combination can cause dangerous cardiac side effects including symptomatic bradycardia. Seek immediate medical attention if you experience unusual fatigue, dizziness, lightheadedness, shortness of breath, chest pain, confusion, or fainting during treatment.

Drug interaction
Daclatasvir has a complex drug interaction profile that requires careful management. The following medications may significantly increase daclatasvir concentrations when used concurrently:

HIV antiviral agents — atazanavir with ritonavir, indinavir, nelfinavir, saquinavir
Cobicistat-containing antiretroviral regimens — e.g., atazanavir/cobicistat, elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate
Anticoagulants — dabigatran etexilate mesylate
Strong CYP3A inhibitors — clarithromycin, itraconazole, ketoconazole, ritonavir

Medications that may decrease daclatasvir concentrations:
Non-nucleoside reverse transcriptase inhibitors (NNRTIs) — efavirenz, etravirine, nevirapine
Moderate CYP3A inducers — bosentan, dexamethasone, modafinil, nafcillin, rifapentine

Additionally, daclatasvir is an inhibitor of P-glycoprotein transporter (P-gp), organic anion transporting polypeptide (OATP) 1B1 and 1B3, and breast cancer resistance protein (BCRP). Administration of Daklinza may increase systemic exposure to medications that are substrates of these transporters, potentially increasing their therapeutic effects or adverse reactions. This is particularly relevant for patients on complex multi-drug regimens for chronic hepatitis C with co-morbid conditions.

Missed dose
Take Daklinza every day at the same regularly scheduled time, with or without food. It is critical not to miss or skip doses during your hepatitis C treatment, as consistent dosing is essential for maintaining effective antiviral drug levels and achieving a sustained virological response. If you do miss a dose and remember within 12 hours, take it as soon as possible. If more than 12 hours have passed, skip the missed dose and resume your regular schedule. For instructions regarding missed doses of other agents in your HCV medication regimen, refer to their respective prescribing information.

Overdose
There is no known specific antidote for an overdose of Daklinza. Treatment of daclatasvir overdose should consist of general supportive measures, including monitoring of vital signs and clinical observation. Because daclatasvir is highly protein-bound (greater than 99%), hemodialysis is unlikely to significantly remove the drug from the bloodstream. If you suspect an overdose, contact emergency medical services immediately.

Storage
Store Daklinza tablets at 77°F (25°C), with temporary excursions permitted between 59°F and 86°F (15°C and 30°C). Keep away from moisture, heat, and direct light. Store all medications out of the reach of children and pets. Do not use after the expiration date.

Disclaimer
We provide only general information about medications which does not cover all directions, possible drug integrations, or precautions. Information at the site cannot be used for self-treatment and self-diagnosis. Any specific instructions for a particular patient should be agreed with your health care adviser or doctor in charge of the case. We disclaim reliability of this information and mistakes it could contain. We are not responsible for any direct, indirect, special or other indirect damage as a result of any use of the information on this site and also for consequences of self-treatment.